The 30th Indonesian International Hospital Medical, Pharmaceutical, Clinical, Laboratories Equipment & Medicine Exhibition 2017 (Hospital Expo 2017) was held from the 18th to 21st of October, 2017 at the Jakarta Convention Center in Jakarta, Indonesia. As the leading global pharmaceutical & medical device B2B online platform, Ddu attended the event, continuing development of their ever growing reputation.
Scientists from the Florida campus of The Scripps Research Institute (TSRI) and Albert Einstein College of Medicine will share in a $9 million grant from the National Institute on Aging, part of the National Institutes of Health, to study how individual genetic differences may form the basis for new therapeutic approaches that target the aging process itself rather than focusing on the treatment of individual diseases.
Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection. Tafinlar in combination with Mekinist is in development to become the first adjuvant treatment specifically for melanoma patients with a BRAF V600 mutation.
More than 80 percent of people who have been diagnosed with attention deficit hyperactivity disorder(ADHD) in adulthood are unlikely to have the condition. This is the conclusion of a new study recently published in the American Journal of Psychiatry.
Johnson & Johnson Group world wide chair Sandi Peterson said: “At Johnson & Johnson Medical Devices Companies, we are committed to broadening our portfolio of products and services to meet the changing needs of our customers around the world.
MIT’s researchers spend a lot of time thinking about digestible technology. In the past couple of years, scientists at the school have developed all sorts of swallowable devices, including a robot fashioned from pig parts designed to remove batteries. The school's Koch Institute in particular has focused on the space, looking at ways in which digestible sensors can be used to monitor things like drug intake.
When bacteria enter our body, they kick-start a powerful immune response. But this chain of reactions doesn't fully account for our immediate responses. Researchers at KU Leuven, Belgium, show that so-called ion channels play a key role as 'first responders'.
GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 50 years and older. Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.